CFRX ContraFect Corporation

0.51
-0.02  -4%
Previous Close 0.53
Open 0.53
Price To Book 7.24
Market Cap 40260645
Shares 79,409,556
Volume 232,683
Short Ratio
Av. Daily Volume 1,387,440

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial noted clinically meaningful data but not statistically significant. Phase 3 trial planned.
CF-301
Serious infections caused byStaph aureus including MRSA

Latest News

  1. ContraFect Presents Additional Positive Data from the Phase 2 Trial of Exebacase at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
  2. The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
  3. Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
  4. ContraFect Announces Publication of Exebacase Data in Antimicrobial Agents and Chemotherapy Journal
  5. ContraFect Announces Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
  6. ContraFect Announces CEO Transition
  7. ContraFect to Present at the Bacteriophage Therapy Summit
  8. CFRX: Planning for Phase 3 Trial of Exebacase in S. Aureus Bacteremia…
  9. ContraFect: 4Q Earnings Snapshot
  10. ContraFect Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
  11. ContraFect to Present at the Oppenheimer 29th Annual Healthcare Conference
  12. ContraFect Announces $6.94 Million in Funding from CARB-X to Support Development of Amurin Platform Against All Gram-negative ESKAPE Pathogens
  13. Glancy Prongay & Murray LLP Continues Investigation on Behalf of ContraFect Corporation Investors (CFRX)
  14. ContraFect Announces Oral Presentation at the 2019 Gordon Research Conference on Mechanisms and Application: Realizing the Potential of Antimicrobial Host Defense Peptides for Human and Veterinary Medicine
  15. Antimicrobials Working Group Announces Updates to Leadership Team
  16. These 4 Healthcare Stocks Are Raising Expectations
  17. ContraFect Announces Additional $2.3 Million in Funding from CARB-X to Support Gram-Negative Lysin Program
  18. CFRX: Exebacase Improves Clinical Outcomes in Phase 2 Trial…
  19. ContraFect’s Exebacase (CF-301) Improved Clinical Outcomes in Staphylococcus aureus Bacteremia including  Right-Sided Endocarditis Compared to Standard of Care Antibiotics Alone in a First-in-Patient Phase 2 Superiority Study
  20. Is ContraFect Corp (CFRX) A Good Stock To Buy?